2023
It is strongly recommended to not conduct, fund, or publish research studies that use spot urine samples with estimating equations to assess individuals’ sodium (salt) intake in association with health outcomes: a policy statement of the World Hypertension League, International Society of Hypertension and Resolve to Save Lives
Campbell N, Whelton P, Orias M, Cobb L, Jones E, Garg R, Willliams B, Khan N, Chia Y, Jafar T, Ide N. It is strongly recommended to not conduct, fund, or publish research studies that use spot urine samples with estimating equations to assess individuals’ sodium (salt) intake in association with health outcomes: a policy statement of the World Hypertension League, International Society of Hypertension and Resolve to Save Lives. Journal Of Hypertension 2023, 41: 683-686. PMID: 36723484, PMCID: PMC10090307, DOI: 10.1097/hjh.0000000000003385.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSpot urine samplesSodium intakeIndividual sodium intakeWorld Hypertension LeagueHealth outcomesUrine samplesHealth outcome associationsOutcome associationsInternational SocietyDietary sodiumHealth OrganizationIntakeHypertensionHealth impactsShort durationOutcomesAssociationSubstantial controversyLiterature reviewPolicy statements
2022
Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients
Coyne DW, Singh AK, Lopes RD, Bailey CK, DiMino TL, Huang C, Connaire J, Rastogi A, Kim SG, Orias M, Shah S, Patel V, Cobitz AR, Wanner C. Three Times Weekly Dosing of Daprodustat versus Conventional Epoetin for Treatment of Anemia in Hemodialysis Patients. Clinical Journal Of The American Society Of Nephrology 2022, 17: 1325-1336. PMID: 35918106, PMCID: PMC9625096, DOI: 10.2215/cjn.00550122.Peer-Reviewed Original ResearchConceptsErythropoiesis-stimulating agentsTimes weekly dosingTRIAL REGISTRY NAMESecondary end pointsTreatment of anemiaEpoetin groupDaprodustat groupEnd pointWeekly dosingREGISTRY NAMEHemoglobin valuesMean changeHypoxia-inducible factor prolyl hydroxylase inhibitorCLINICAL TRIAL REGISTRY NAMEPrincipal secondary end pointTreatment-emergent adverse eventsIntravenous iron doseIntravenous iron usePrimary end pointChronic kidney diseaseMean hemoglobin valuesEvaluation periodProlyl hydroxylase inhibitorBaseline hemoglobinPrevalent hemodialysisBedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension
Stergiou G, Brunström M, MacDonald T, Kyriakoulis KG, Bursztyn M, Khan N, Bakris G, Kollias A, Menti A, Muntner P, Orias M, Poulter N, Shimbo D, Williams B, Adeoye AM, Damasceno A, Korostovtseva L, Li Y, Muxfeldt E, Zhang Y, Mancia G, Kreutz R, Tomaszewski M. Bedtime dosing of antihypertensive medications: systematic review and consensus statement: International Society of Hypertension position paper endorsed by World Hypertension League and European Society of Hypertension. Journal Of Hypertension 2022, 40: 1847-1858. PMID: 35983870, DOI: 10.1097/hjh.0000000000003240.Peer-Reviewed Original ResearchConceptsAntihypertensive drugsAntihypertensive medicationsBedtime dosingOutcome trialsDrug dosingClinical practiceEfficient medical interventionsHypertension position paperMorning BP surgeNight-time hypertensionAntihypertensive drug therapyAntihypertensive drug treatmentSingle morning doseBlood pressure profileEffective treatment strategiesWorld Hypertension LeagueInternational SocietyAntihypertensive treatmentBedtime administrationBP controlBP surgeMorning doseMorning dosingCardiovascular eventsAdverse prognosis2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action
Campbell NRC, Whelton PK, Orias M, Wainford RD, Cappuccio FP, Ide N, Neal B, Cohn J, Cobb LK, Webster J, Trieu K, He FJ, McLean RM, Blanco-Metzler A, Woodward M, Khan N, Kokubo Y, Nederveen L, Arcand J, MacGregor GA, Owolabi MO, Lisheng L, Parati G, Lackland DT, Charchar FJ, Williams B, Tomaszewski M, Romero CA, Champagne B, L’Abbe M, Weber MA, Schlaich MP, Fogo A, Feigin VL, Akinyemi R, Inserra F, Menon B, Simas M, Neves MF, Hristova K, Pullen C, Pandeya S, Ge J, Jalil JE, Wang JG, Wideimsky J, Kreutz R, Wenzel U, Stowasser M, Arango M, Protogerou A, Gkaliagkousi E, Fuchs FD, Patil M, Chan AW, Nemcsik J, Tsuyuki RT, Narasingan SN, Sarrafzadegan N, Ramos ME, Yeo N, Rakugi H, Ramirez AJ, Álvarez G, Berbari A, Kim CI, Ihm SH, Chia YC, Unurjargal T, Park HK, Wahab K, McGuire H, Dashdorj NJ, Ishaq M, Ona DID, Mercado-Asis LB, Prejbisz A, Leenaerts M, Simão C, Pinto F, Almustafa BA, Spaak J, Farsky S, Lovic D, Zhang XH. 2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action. Journal Of Human Hypertension 2022, 37: 428-437. PMID: 35581323, PMCID: PMC9110933, DOI: 10.1038/s41371-022-00690-0.Peer-Reviewed Original Research
2021
Is Isolated Diastolic Hypertension an Important Phenotype?
Romero CA, Tabares AH, Orias M. Is Isolated Diastolic Hypertension an Important Phenotype? Current Cardiology Reports 2021, 23: 177. PMID: 34657205, PMCID: PMC8753786, DOI: 10.1007/s11886-021-01609-w.Peer-Reviewed Original ResearchConceptsNarrow pulse pressureDiastolic hypertensionCardiovascular riskPulse pressureLong-term cardiovascular riskRecent FindingsRecent guidelinesHypertension subgroupIDH definitionsIDH prevalenceHypertensive patientsYounger patientsRisk stratificationEpidemiological characteristicsTherapeutic decisionsPharmacological interventionsHypertension phenotypesCutoff levelHypertensionImportant subgroupPatientsPathophysiologyRiskSubgroupsIDHLong term
2020
Standardized treatment to improve hypertension control in primary health care: The HEARTS in the Americas Initiative
DiPette DJ, Goughnour K, Zuniga E, Skeete J, Ridley E, Angell S, Brettler J, Campbell NRC, Coca A, Connell K, Doon R, Jaffe M, Lopez‐Jaramillo P, Moran A, Orias M, Pineiro DJ, Rosende A, González YV, Ordunez P. Standardized treatment to improve hypertension control in primary health care: The HEARTS in the Americas Initiative. Journal Of Clinical Hypertension 2020, 22: 2285-2295. PMID: 33045133, PMCID: PMC8029673, DOI: 10.1111/jch.14072.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAntihypertensive medicationsCardiovascular diseaseTreatment protocolHypertension controlBurden of CVDCVD secondary preventionEffective antihypertensive medicationsMajor hypertension guidelinesRisk factor mitigationControl of hypertensionFixed-dose combinationPrimary health carePost-program implementationCommunity-based programsHypertension guidelinesSecondary preventionBlood pressureCVD burdenInitial treatmentPharmacologic protocolRisk factorsStandardized treatmentMedication formulariesSingle pillHypertensionGlobal Dialysis Perspective: Argentina.
Orias M, Rosa Diez GJ. Global Dialysis Perspective: Argentina. Kidney360 2020, 1: 676-679. PMID: 35372938, PMCID: PMC8815540, DOI: 10.34067/kid.0001222019.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsSecond Consensus on Treatment of Patients Recently Diagnosed With Mild Hypertension and Low Cardiovascular Risk
Morales-Salinas A, Olsen MH, Kones R, Kario K, Wang J, Beilin L, Weber MA, Yano Y, Burrell L, Orias M, Cameroon DA, Lavie CJ, Ventura H, Sundström J, de Simone G, Coca A, Rumana U, Marrugat J. Second Consensus on Treatment of Patients Recently Diagnosed With Mild Hypertension and Low Cardiovascular Risk. Current Problems In Cardiology 2020, 45: 100653. PMID: 32828558, DOI: 10.1016/j.cpcardiol.2020.100653.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHypertension and kidney disease progression.
Rigo D, Orias M. Hypertension and kidney disease progression. Clinical Nephrology 2020, 93: 103-107. PMID: 31549630, DOI: 10.5414/cnp92s118.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney disease progressionDisease progressionCases of CKDHypertension-attributed nephropathyRisk of progressionAfrican American patientsGene risk variantsClinical suspicionHypertensive nephropathyKidney diseaseUnknown etiologyCommon findingProgressionHypertensionNephropathyPatientsRisk variantsGenetic backgroundEtiologyDiseaseDiagnosisSuspicion
2016
2016 Dietary Salt Fact Sheet and Call to Action: The World Hypertension League, International Society of Hypertension, and the International Council of Cardiovascular Prevention and Rehabilitation
Campbell NR, Lackland DT, Niebylski ML, Orias M, Redburn KA, Nilsson PM, Zhang X, Burrell L, Horiuchi M, Poulter NR, Prabhakaran D, Ramirez AJ, Schiffrin EL, Schutte AE, Touyz RM, Wang J, Weber MA, Prevention and Rehabilitation I. 2016 Dietary Salt Fact Sheet and Call to Action: The World Hypertension League, International Society of Hypertension, and the International Council of Cardiovascular Prevention and Rehabilitation. Journal Of Clinical Hypertension 2016, 18: 1082-1085. PMID: 27515460, PMCID: PMC8032122, DOI: 10.1111/jch.12894.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHigh Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Nephrology
Campbell NR, Khalsa T, Executive: W, Lackland DT, Niebylski ML, Nilsson PM, Redburn KA, Orias M, Zhang X, Executive: I, Burrell L, Horiuchi M, Poulter NR, Prabhakaran D, Ramirez AJ, Schiffrin EL, Touyz RM, Wang J, Weber MA, Organization W, Federation I, Prevention and Rehabilitation I, Society of Nephrology I. High Blood Pressure 2016: Why Prevention and Control Are Urgent and Important. The World Hypertension League, International Society of Hypertension, World Stroke Organization, International Diabetes Foundation, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Nephrology. Journal Of Clinical Hypertension 2016, 18: 714-717. PMID: 27316336, PMCID: PMC8031792, DOI: 10.1111/jch.12840.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2015
Resources for Blood Pressure Screening Programs in Low Resource Settings: A Guide From the World Hypertension League
Mangat BK, Campbell N, Mohan S, Niebylski ML, Khalsa TK, Berbari AE, Cloutier L, Jean-Charles R, Kenerson J, Lemogoum D, Orias M, Veiga E, Zhang XH. Resources for Blood Pressure Screening Programs in Low Resource Settings: A Guide From the World Hypertension League. Journal Of Clinical Hypertension 2015, 17: 418-420. PMID: 25689038, PMCID: PMC8031891, DOI: 10.1111/jch.12499.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNovel RAAS agonists and antagonists: clinical applications and controversies
Romero CA, Orias M, Weir MR. Novel RAAS agonists and antagonists: clinical applications and controversies. Nature Reviews Endocrinology 2015, 11: 242-252. PMID: 25666495, PMCID: PMC7097622, DOI: 10.1038/nrendo.2015.6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAngiotensin receptor blockersRelative risk reductionBlood pressure homeostasisRAAS peptidesAldosterone systemReceptor blockersCardiorenal diseaseVascular injuryPressure homeostasisReceptor densityTarget organsAutocrine systemEnzyme inhibitorsVascular structuresClinical applicationRisk reductionVariety of sitesHaemodynamicsBlockersAgonistsInjuryAntagonistRAASDiseasePeptides
2014
Electron Microscopy Contribution to Diagnosing Transplant Glomerulopathy: A Single-Center Experience
Rigo D, Barrón MB, Martinatto C, Mukdsi J, Orías M, Novoa P. Electron Microscopy Contribution to Diagnosing Transplant Glomerulopathy: A Single-Center Experience. Transplantation Proceedings 2014, 46: 2975-2980. PMID: 25420804, DOI: 10.1016/j.transproceed.2014.07.008.Peer-Reviewed Original ResearchConceptsInterstitial fibrosis/tubular atrophyDeceased donor renal transplantLower graft survivalPercent of patientsKidney transplant biopsiesSingle-center experienceIdentification of patientsGraft dysfunctionGraft survivalRenal transplantTransplant biopsiesTransplant glomerulopathyGraft pathologyTubular atrophyStudy criteriaHistologic changesPatientsAverage evolution timeEarly changesAccurate diagnosisLight microscopyTransplantation timeBiopsyDiagnosisTransplantationEstimated GFR or Albuminuria: Which One Is Really Associated With Resistant Hypertension?
Romero CA, Peixoto AJ, Orias M. Estimated GFR or Albuminuria: Which One Is Really Associated With Resistant Hypertension? Seminars In Nephrology 2014, 34: 492-497. PMID: 25416657, DOI: 10.1016/j.semnephrol.2014.08.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLow estimated glomerular filtration rateEstimated glomerular filtration rateResistant hypertensionGlomerular filtration rateFiltration rateHigh cardiovascular risk groupTarget organ damageComplications of hypertensionCardiovascular risk groupsHigher sympathetic activityEndothelial dysfunctionFluid overloadSympathetic activityOrgan damageKidney diseaseRisk groupsHigh prevalenceHypertensionMicroalbuminuriaPrevalenceDifferent phenotypesPhenotypeAlbuminuriaComplicationsGFR
2013
Hemodynamic circulatory patterns in young patients with predominantly diastolic hypertension
Romero CA, Alfie J, Galarza C, Waisman G, Peixoto AJ, Tabares AH, Orias M. Hemodynamic circulatory patterns in young patients with predominantly diastolic hypertension. International Journal Of Cardiology Cardiovascular Risk And Prevention 2013, 7: 157-162. PMID: 23403215, DOI: 10.1016/j.jash.2013.01.001.Peer-Reviewed Original ResearchConceptsSystemic vascular resistanceStroke volume indexDiastolic hypertensionCardiac indexHemodynamic patternsHeart rateTotal arterial compliance indexAmbulatory blood pressure monitoringHigher systemic vascular resistanceNormal systemic vascular resistanceArterial compliance indexLow cardiac indexHigher cardiac indexBlood pressure monitoringSVR groupVascular resistanceYounger patientsBlood pressureHypertensive individualsHypertension patientsPathophysiologic mechanismsMean agePulse pressureHypertensionPressure monitoringDoes Kidney Disease Cause Hypertension?
Peixoto AJ, Orias M, Desir GV. Does Kidney Disease Cause Hypertension? Current Hypertension Reports 2013, 15: 89-94. PMID: 23344662, DOI: 10.1007/s11906-013-0327-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney diseaseRenal functionStructural kidney diseaseGlomerular filtration ratePlasmin-mediated activationExtracellular fluid volumeProteinuric glomerular diseasesPolycystic kidney diseaseChronic hypertensionHypertension increasesEpithelial sodium channelSodium retentionFiltration rateGlomerular diseaseHypertensionCurrent evidenceDiseaseSodium channelsFluid volumeDetectable changeSevere reductionMost casesProteinuriaPatients
2012
Uremic pruritus in hemodialysis patients: treatment with desloratidine versus gabapentin
Marquez D, Ramonda C, Lauxmann JE, Romero CA, Vukelic VL, Martinatto C, Barrón B, Novoa PA, Peixoto AJ, Orías M. Uremic pruritus in hemodialysis patients: treatment with desloratidine versus gabapentin. Brazilian Journal Of Nephrology 2012, 34: 148-152. PMID: 22850916, DOI: 10.1590/s0101-28002012000200007.Peer-Reviewed Original ResearchConceptsUremic pruritusPruritus scoreOne-week washout periodOne-week runAlternate regimenChronic hemodialysisPrimary endpointExcessive sedationVAS scoresDialysis patientsHemodialysis patientsWashout periodMarginal efficacyClinical trialsPruritusSignificant reliefEffective treatmentNineteen subjectsSide effectsGabapentinPatientsMore weeksDesloratadineStatistical significanceTreatment
2011
Preemptive Kidney Transplantation: Experience in Two Centers
Rigo DH, Ziraldo L, Di Monte L, Jimenez MP, Giotto AP, Gutierrez L, Rodriguez I, Orias M, Novoa PA. Preemptive Kidney Transplantation: Experience in Two Centers. Transplantation Proceedings 2011, 43: 3355-3358. PMID: 22099795, DOI: 10.1016/j.transproceed.2011.09.083.Peer-Reviewed Original ResearchConceptsPreemptive kidney transplantEnd-stage renal diseaseDelayed graft functionSubclinical rejectionKidney transplantDeceased donorsInterstitial fibrosis/tubular atrophyDeceased donor groupChronic allograft nephropathyPreemptive kidney transplantationRenal replacement therapyDonor kidney transplantsLong-term dialysisQuality of lifeAllograft nephropathyGraft functionKidney transplantationPreemptive transplantationMonths posttransplantationSerum creatinineTransplantation centersRenal diseaseTubular atrophyCalcineurin inhibitorsPoor outcomeCan aluminum‐based binders be used safely?
Jimenez PM, Douthat W, Orías M. Can aluminum‐based binders be used safely? Seminars In Dialysis 2011, 24: 430-431. PMID: 21801208, DOI: 10.1111/j.1525-139x.2011.00889.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements